Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to $145448.0.

  • Profound Medical's Gains from Sales and Divestitures changed N/A to $145448.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $145448.0, marking a year-over-year change of. This contributed to the annual value of $228774.0 for FY2024, which is 4110.44% up from last year.
  • As of Q3 2025, Profound Medical's Gains from Sales and Divestitures stood at $145448.0.
  • In the past 5 years, Profound Medical's Gains from Sales and Divestitures registered a high of $228774.0 during Q4 2024, and its lowest value of $13333.0 during Q1 2025.
  • In the last 3 years, Profound Medical's Gains from Sales and Divestitures had a median value of $145448.0 in 2025 and averaged $112603.8.
  • The largest annual percentage gain for Profound Medical's Gains from Sales and Divestitures in the last 5 years was 4110.44% (2024), contrasted with its biggest fall of 4110.44% (2024).
  • Profound Medical's Gains from Sales and Divestitures (Quarter) stood at $162131.0 in 2023, then skyrocketed by 41.1% to $228774.0 in 2024, then crashed by 36.42% to $145448.0 in 2025.
  • Its last three reported values are $145448.0 in Q3 2025, $13333.0 for Q2 2025, and $13333.0 during Q1 2025.